Abstract:Aim: To develop a combined population pharmacokinetic model (PPK) to assess the magnitude and variability of exposure to both clozapine and its primary metabolite norclozapine in Chinese patients with refractory schizophrenia via sparse sampling with a focus on the effects of covariates on the pharmacokinetic parameters. Methods: Relevant patient concentration data ( eg , demographic data, medication history, dosage regimen, time of last dose, sampling time, concentrations of clozapine and norclozapine, etc ) were collected using a standardized data collection form. The demographic characteristics of the patients, including sex, age, weight, body surface area, smoking status, and information on concomitant medications as well as biochemical and hematological test results were recorded. Persons who had smoked 5 or more cigarettes per day within the last week were defined as smokers. The concentrations of clozapine and norclozapine were measured using a HPLC system equipped with a UV detector. PPK analysis was performed using NONMEM. Age, weight, sex, and smoking status were evaluated as main covariates. The model was internally validated using normalized prediction distribution errors. Results: A total of 809 clozapine concentration data sets and 808 norclozapine concentration data sets from 162 inpatients (74 males, 88 females) at multiple mental health sites in China were included. The one-compartment pharmacokinetic model with mixture error could best describe the concentration-time profiles of clozapine and norclozapine. The population-predicted clearance of clozapine and norclozapine in female nonsmokers were 21.9 and 32.7 L/h, respectively. The population-predicted volumes of distribution for clozapine and norclozapine were 526 and 624 L, respectively. Smoking was significantly associated with increases in the clearance (clozapine by 45%; norclozapine by 54.3%). The clearance was significantly greater in males than in females (clozapine by 20.8%; norclozapine by 24.2%). The clearance of clozapine and norclozapine did not differ significantly between Chinese patients and American patients. Conclusion: Smoking and male were significantly associated with a lower exposure to clozapine and norclozapine due to higher clearance. This model can be used in individualized drug dosing and therapeutic drug monitoring.

Clinical and pharmacological factors influencing serum clozapine and norclozapine levels

Gender, Age, Smoking Behaviour And Plasma Clozapine Concentrations In 193 Chinese Inpatients With Schizophrenia

Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia

From strict quarantine to an optimized policy: Are we psychologically prepared?

Effect of Clonazepam Co-Administered with Clozapine on the Serum Clozapine and Norclozapine Concentration of Patients with Schizophrenia: A Retrospective Survey.

Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

Effect of clonazepam co-administered with clozapine on the serum clozapine and norclozapine concentraiton of paitents with schizophrenia：A Retrospecitve Survey

Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement

Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients

Individual differences in the pharmacokinetics of clozapine in healthy Chinese adults

Population Pharmacokinetics of Clozapine and Its Primary Metabolite Norclozapine in Chinese Patients with Schizophrenia

Higher Plasma Drug Concentration in Clozapine-treated Schizophrenic Patients With Side Effects of Obsessive/Compulsive Symptoms

The effect of smoking and sex on pharmacokinetics of clozapine and norclozapine

Evaluation of major adverse events of clozapine based on accordance to an international titration guideline

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

Interindividual Variation In Relative Cyp1a2/3a4 Phenotype Influences Susceptibility Of Clozapine Oxidation To Cytochrome P450-Specific Inhibition In Human Hepatic Microsomes

Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine

Clozapine metabolism and cardiotoxicity: A prospective longitudinal study

Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine